GlassScriptPhysician profile
Cassandra Ai Ho
NPI 1124739271
$5,743.58
in general payments reported to CMS, 2019-2025
24 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,823 · 2024: $2,132 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,545 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,544.59 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $940.91 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $732.91 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $672.21 | 2023-2025 | Tremfya |
| Amgen INC. | $496.09 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $446.07 | 2023-2025 | |
| Lilly USA, LLC | $439.36 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $262.91 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $235.91 | 2023-2025 | Zoryve |
| Ucb, INC. | $230.52 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $224.60 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $220.30 | 2023-2024 | Ilumya, Winlevi |
| Regeneron Healthcare Solutions, INC. | $209.37 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $170.80 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.62 | 2024 | Cabtreo |
| Journey Medical Corporation | $82.61 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $75.57 | 2023-2025 | Opzelura |
| Organon LLC | $56.56 | 2025 | Vtama |
| Dermavant Sciences, INC. | $36.47 | 2023-2024 | Vtama |
| Biocon Biologics INC | $28.90 | 2024 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.56 | 2023 | Spevigo |
| Almirall LLC | $21.00 | 2025 | Klisyri |
| Helsinn Therapeutics (U.S.), INC. | $20.01 | 2023 | Valchlor |
| Krystal Biotech INC | $16.18 | 2025 | Vyjuvek |
| Convatec INC. | $15.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.